LUNG Financials

Income Statement
MetricQ3 2026Q2 2026Q1 2026Q4 2025Q3 2025
Revenue
22.8M
+0.3%
22.8M
+10.5%
20.6M
-8.9%
22.6M
+5.1%
21.5M
Cost of Revenue
5.4M
+8.4%
5.0M
+10.4%
4.5M
-10.2%
5.1M
-7.2%
5.5M
Gross Profit
17.4M
-1.9%
17.7M
+10.6%
16.0M
-8.5%
17.5M
+9.3%
16.1M
Operating Expenses
24.9M
-7.1%
26.8M
-7.6%
29.0M
+5.7%
27.4M
-9.9%
30.4M
R&D
4.9M
-3.4%
5.0M
+2.8%
4.9M
+6.9%
4.6M
-5.4%
4.8M
SG&A
20.0M
-8.0%
21.8M
-9.7%
24.1M
+5.4%
22.9M
-10.7%
25.6M
Operating Income
-7490000
+17.3%
-9057000
+30.1%
-12956000
-30.8%
-9903000
+31.2%
-14393000
EBITDA
-7275000
+17.7%
-8835000
+30.6%
-12736000
-31.7%
-9672000
+31.6%
-14147000
Net Income
-8394000
+16.7%
-10080000
+26.2%
-13654000
-31.0%
-10425000
+25.3%
-13957000
EPS (Basic)
$-0.19
+20.8%
$-0.24
+27.3%
$-0.33
-32.0%
$-0.25
+26.5%
$-0.34
EPS (Diluted)
$-0.19
+20.8%
$-0.24
+27.3%
$-0.33
-32.0%
$-0.25
+26.5%
$-0.34
Shares (Diluted)
43.2M
+1.7%
42.5M
+1.4%
41.9M
+1.1%
41.4M
+1.2%
40.9M
Pulmonx (LUNG) — Financials